


Hot Topics in Atherosclerosis and Cardiovascular Disease


DATES:	Wednesday 4 – Friday 6 July 2018	Accreditation / endorsement: CPD via the Royal College of Physicians approved British Dietetic Association endorsement (BDA) endorsed
LOCATION:	Warwick Arts Centre, University of Warwick, Coventry CV4 7AL	
CONFERENCE ORGANISING COMMITTEE:		
CHAIR:	<i>Dr Nigel CAPPS</i> - Consultant Chemical Pathologist, Telford	
LOCAL HOSTS:	<i>Professor Elizabeth HUGHES</i> - Director of Education and Quality HEE (London and South East); West Midlands Regional Postgraduate Dean, Birmingham <i>Professor Mike KHAN</i> - Associate Professor of Medicine at the University of Warwick, Coventry	
COMMITTEE:	<i>Mr Stephen BOLEY</i> – Chairman, HEART UK <i>Dr Dev DATTA</i> - Consultant in Biochemistry & Metabolic Medicine, Cardiff, Wales <i>Dr Arun GUPTA</i> – GP, South Lewisham <i>Linda MAIN</i> – Dietetic Advisor, HEART UK <i>Mrs Michaela NUTTALL</i> - vice chair Healthcare Committee <i>Jules PAYNE</i> – Chief Executive, HEART UK <i>Dr Alan REES</i> – Medical Director, HEART UK <i>Dr Handrean SORAN</i> – Consultant Physician & Endocrinologist / Honorary Senior Lecturer, Manchester	

PROGRAMME SUMMARY:

	MORNING	MID MORNING	MIDDAY	AFTERNOON	EVENING
WED	Hyperlipidaemia Education + Lp(a) Study Day HEART UK Committee Meetings				Sponsored Symposia 1 2 3 HEART UK Annual General Meeting Welcome Buffet Reception
THURS	Medical + Scientific Programme Primary + Health Care Programme			Clinical Lipidology Live! Heart Healthy Walk Myant Lecture	Conference Dinner and dance
FRI	Moderated Poster Session Medical + Scientific Programme Abstract Session Primary + Health Care Programme Abstract Session			Presentation of Abstract Prizes Closing Debate	

WEDNESDAY 4 JULY

07:00 – 09:00	BREAKFAST (residential guests only)	1 st floor, Rootes Building Restaurant
08:00	REGISTRATION OPENS	Arts Centre foyer
09:00 – 10:30 (1hr 30 mins)	HEART-UK-MS&R Committee meeting Chair: Handrean Soran Deputy Chair: Dev Datta	National Grid Room, 1 st floor, Arts Centre
09:00 – 11:00	STUDY DAY REFRESHMENTS	Butterworth Hall, Arts Centre
11:00 – 17:00	Exhibition build	Mead Gallery, 1 st floor, Arts Centre
11:00 – 16:15	Hyperlipidaemia Education + Lp(a) Study Day: <i>Invitation to: Primary care • GP's • GP Registrars • Cardiovascular and Lipid Clinic Nurses • Practice Nurses • Genetics Specialist Nurses • Dietitians • Nutritionists • Scientists • PhD students • Consultants • SpR's working within clinical chemistry, endocrine and diabetes • Nurses and others involved in the field of lipidology and cardiovascular risk.</i> Organised by: Handrean SORAN	Cinema, Arts Centre
	Co-Chairs: Handrean SORAN + Safwaan ADAM	
11:00 – 11:30 (30 mins)	SPEAKER 1: Optimising treatment of Hyperlipidaemia: quantitative evaluation of UK, USA and European guidelines Evidence strongly favours therapeutic LDL concentration targets in hypercholesterolaemia Professor Paul DURRINGTON Professor of Medicine Division of Cardiovascular Sciences, University of Manchester Manchester, UK	
11:30 – 11:40	Discussion	
11:40 – 12:05 (25 mins)	SPEAKER 2: Cardiovascular risk in chronic kidney disease and its management Professor Phil KALRA Consultant Nephrologist, Salford Royal NHS Foundation Trust, University of Manchester, Manchester, UK	
12:05 – 12:15	Discussion	
12:15 – 12:40 (25 mins)	SPEAKER 3: Lipodystrophy: diagnosis and management Diagnosis and management of syndromes of lipodystrophy Dr Anna STEARS Consultant in Diabetes and Endocrinology Addenbrooke's Hospital, Diabetes and Endocrinology Cambridge, UK	
12:40 – 12:50	Discussion	
12:50	Session close	
12:50 – 13:50	STUDY DAY LUNCH + NETWORKING	Butterworth Hall, Arts Centre
13:50 – 16:15	Hyperlipidaemia Education + Lp(a) Study Day continued: Supported by:  <small>A subsidiary of Ionis Pharmaceuticals, Inc.</small>	Cinema, Arts Centre

	Co-Chairs: <i>Jai CEGLA + Benjamin JONES</i>	
13:50 – 14:15 (25 mins)	SPEAKER 5: Lipoprotein(a): its value as a CV risk factor and how to address it Describing the role of lipoprotein(a) as an independent risk factor for atherosclerotic disease and discuss potential treatments <i>Professor Klaus G. PARHOFER</i> Professor of Endocrinology and Metabolism Ludwig Maximilians University Munich Germany Munich, GERMANY	
14:15 – 14:25	Discussion	
14:25 – 14:50 (25 mins)	SPEAKER 6: Lp(a) in children <i>Professor Kurt WIDHALM</i> Professor for Clinical Nutrition and Pediatrics President: Academic Institute for Clinical Nutrition Vienna, AUSTRIA	
14:50 – 15:00	Discussion	
15:00 – 15:15	Comfort break	
	Co-Chairs: <i>Michael FRANCE + Robert CRAMB</i>	
15:15 – 15:40 (25 mins)	SPEAKER 7: Lipoprotein (a) as a therapeutic target An overview of my clinical research assessing the role of Lipoprotein (a) reduction with Apheresis in Refractory Angina, as well as new emerging therapies for raised Lipoprotein (a). <i>Dr Tina KHAN</i> Academic Clinical Lecturer/ Cardiology Specialist Registrar Imperial College/ Royal Brompton and Harefield NHS Foundation Trust, London, UK	
15:40 – 15:50	Discussion	
15:50 – 16:10 (20 mins)	SPEAKER 8: Lp(a) – The Lipoprotein(a) Foundation, a risk marker for cardiovascular disease – A patient’s story The Vision of the Lipoprotein(a) Foundation is to live in a world where high Lipoprotein(a) is routinely diagnosed, treated and family screened. <i>Mrs Sandra REVILL TREMULIS</i> Founder and President The Lipoprotein(a) Foundation Chairman and CEO San Carlos, California, USA	
16:10 – 16:15	Discussion	
16:15	Close of session	
16:30 – 18:00 (1hr 30 mins)	HEART UK Health Care Committee meeting HOST: <i>Linda Main</i>	<i>National Grid Room, 1st floor, Arts Centre</i>
16:30 - 17:10 (40 mins)	SPONSORED SYMPOSIA 1:  <i>Programme development by sponsor</i>	<i>Butterworth Hall, Arts Centre</i>
17:10 – 17:20	Changeover	

17:20 – 18:00
(40 mins)

SPONSORED SYMPOSIA 2:



A subsidiary of Ionis Pharmaceuticals, Inc.

Programme development by sponsor

Butterworth Hall, Arts Centre

18:00 – 18:10

Changeover

18:10 – 18:50
(40 mins)

SPONSORED SYMPOSIA 3:

Butterworth Hall, Arts Centre



Cardiovascular

Programme development by sponsor

18:50

Welcome drinks available

19:00 – 19:30

HEART UK AGM

National Grid Room, Arts Centre

19:30 – 22:00

WELCOME BUFFET RECEPTION

Mead Gallery, 1st floor, Arts Centre

19:40 – 19:45

HEART UK welcome

Mr Stephen BOLEY, Chairman, HEART UK

19:45 – 19:50

SPONSOR WELCOME

19:50

Presentation of the Rianna WINGETT award

Presented by *ALAN REES*

22:00

Evening concludes

THURSDAY 5 JULY

07:00 – 09:00

BREAKFAST (residential guests only)

1st floor, Rootes Building Restaurant

08:00

REGISTRATION OPENS

Arts Centre foyer

08:00 – 09:00

Lipid Interest Group meeting

Chancellors, 2nd floor, Rootes Building

HOST: *Alison POTTLE*

08:30 – 09:10

REFRESHMENTS, NETWORKING + EXHIBITION

Mead Gallery, 1st floor, Arts Centre

09:10 – 11:00

SESSION A: Medical & Scientific

Butterworth Hall, Arts Centre

Hot Topics in Atherosclerosis – Part One

09:10 – 09:20

Introduction:

(10 mins)

Mr Stephen BOLEY, Chairman, HEART UK

Dr Alan REES, Medical Director, HEART UK

Co-chairs: *Nigel CAPPS + Mike KHAN*

09:20 – 09:40

PLENARY SPEAKER 1:

(20 mins)

CETP inhibition – the Oxford REVEAL study

This talks will describe the story of CETP inhibition to date, and the results of the 30,000-patient REVEAL trial of anacetrapib.

Dr Louise BOWMAN

Associate Professor of Clinical Trials and Epidemiology

University of Oxford, Nuffield Department of Population Health, Oxford, UK

09.40 – 09:45

Discussion

	09:45 – 10:05 (20 mins)	<p>PLENARY SPEAKER 2: HDL – reasons of previous clinical futility and opportunities for future clinical utility Exploitation of HDL needs novel biomarkers that unlike “HDL-cholesterol” reflect functionality of HDL <i>Professor Arnold VON ECKARDSTEIN</i> Chairman of the Institute University of Zurich and University Hospital of Zurich, Institute of Clinical Chemistry Zurich, SWITZERLAND</p>	
	10:05 – 10:10	Discussion	
	10:10 – 10:30 (20 mins)	<p>PLENARY SPEAKER 3: Inflammation in atherosclerosis and coronary artery disease Inflammation in coronary arteries, does it matter and what can be done about it? <i>Professor Sheila FRANCIS</i> Head of Department University of Sheffield, Infection, Immunity and Cardiovascular Disease, Medical School Sheffield, UK</p>	
	10:30 – 10:35	Discussion	
	10:35 – 10:55 (20 mins)	<p>PLENARY SPEAKER 4: Inclisiran – the story so far Exploring the mechanism of action of inclisiran, data from early phase trials, details of ongoing studies and plans for a forthcoming cardiovascular outcome trial. <i>Dr David PREISS</i> Associate Professor University of Oxford, Nuffield Department of Population Health, Oxford, UK</p>	
	10:55 – 11:00	Discussion	
11:00 – 11:30	REFRESHMENTS, NETWORKING + EXHIBITION		Mead Gallery, 1 st floor, Arts Centre
11:30 – 13:15	SESSION B: Medical & Scientific Hot Topics in Atherosclerosis – Part Two <i>Co-chairs: Dev DATTA + Gordon FERNS</i>		SESSION C: Primary & Health Care Sex and the Circulation <i>Co-chairs: Alan BEGG + Michaela NUTTALL</i>
	11:30 – 12:00 (30 mins)	<p>SPEAKER 5: Non alcoholic fatty liver disease (NAFLD) update NAFLD is very common in patients with CVD risk factors: how should NAFLD be diagnosed and which patients should be referred for specialist investigation? <i>Professor Christopher D BYRNE</i> Professor Endocrinology & Metabolism Human Development and Health Academic Unit Faculty of Medicine University of Southampton, Southampton General Hospital Southampton, UK</p>	<p>HC SPEAKER 5: Public health and primary care commissioning for vascular health – the role of the public health commissioner and current practice/priorities in commissioning and delivering services <i>Mrs Gillian FIUMICELLI</i> Head of Vascular Disease Prevention Programme Public Health Bromley, London Borough of Bromley, UK</p>
	12:00 – 12:05	Discussion	12:00 – 12:05
	12:05 – 12:35 (30 mins)	<p>SPEAKER 6: Bariatric surgical approaches in managing obesity <i>Mr John BARRY</i> Surgeon Welsh Institute of Metabolic and Obesity Surgery, Morriston Hospital, Swansea, Wales, UK</p>	<p>HC SPEAKER 6: Cardiovascular disease: lifetime risk for women Awareness of recommendations for women’s cardiovascular health and an individualised approach may lead to equitable provision; recent SWEDEHEART data 2003-2013 question progress and must keep us vigilant. <i>Dr Jane FLINT BRIDGEWATER</i> Honorary Consultant Cardiologist, Dudley Group NHSFT Medical Director Action Heart Cardiovascular Prevention & Rehabilitation Programme, Russell’s Hall Hospital Dudley, UK</p>

	12:35 – 12:40	Discussion	12:35 – 12:40	Discussion	
	12:40 – 13:10 (30 mins)	SPEAKER 7: Metabolic improvements in patients with impaired glucose homeostasis following bariatric surgery <i>Professor Jeffrey STEPHENS</i> Clinical Professor of Diabetes, Swansea University Consultant Physician, Morriston Hospital Swansea, Wales, UK	12:40 – 13:10 (30 mins)	HC SPEAKER 7: Men and CVD There is a gender gap of 6-7 yrs. in favour of women, why should that be??? <i>Professor Michael KIRBY</i> The University of Hertfordshire Centre for Research in Primary and Community Care University of Hertfordshire, Hatfield, UK	
	13:10 – 13:15	Discussion	13:10 – 13:15	Discussion	
13:15 – 14:30 (75 mins)	LUNCH, NETWORKING + EXHIBITION				<i>Mead Gallery, 1st floor, Arts Centre</i>
13:15 – 14:30	Simon Broome Committee meeting Host: <i>Nigel CAPPS</i>				<i>National Grid Room, 1st floor, Arts Centre</i>
14:30 – 16:00	Clinical Lipidology Live! Interactive case study session in a panel format with perspectives from a cardiologist, lipidologist and GP Organiser: Dev Datta Facilitator: <i>Dr Dev DATTA</i> Consultant in Biochemistry & Metabolic Medicine, Cardiff, Wales				<i>Butterworth Hall, Arts Centre</i>
16:00 – 16:30	Heart healthy walk Host: HEART UK Fundraising Manager, <i>Charlotte HOARE</i> will be leading this heart healthy walk designed to energise everyone at the end of a busy day! Depart from outside Butterworth Hall after Clinical Lipidology Live				
16:00 – 16:45	REFRESHMENTS, NETWORKING + EXHIBITION				<i>Mead Gallery, 1st floor, Arts Centre</i>
16:45 – 18:00	SESSION D: Medical & Scientific Chair: <i>Alan REES</i>				<i>Butterworth Hall, Arts Centre</i>
	16:45 – 17:00 (15 mins)	HEART UK CHARITY UPDATE <i>Miss Jules PAYNE</i> Chief Executive, HEART UK			
	17:00 – 18:00 (60 mins) NO Q+A	SPEAKER 9: MYANT LECTURE: Nuclear receptors in the control of metabolic and cardiovascular disease Nuclear receptors as therapeutic targets for cardiometabolic diseases – a story from bench-to-bedside <i>Professor Bart STAELS</i> Head of INSERM Unit 1011, University of Lille, Institut Pasteur de Lille, University Hospital Lille Lille, FRANCE			
18:00	Conference close				
19:15 – 19:45	CONFERENCE PRE DINNER DRINKS				<i>Helen Martin Studio, Arts Centre</i>
19:45 – 23:30	CONFERENCE DINNER AND ENTERTAINMENT				<i>Butterworth Hall, Arts Centre</i>
23:30	Bar closes				
24:00	Evening concludes				

FRIDAY 6 JULY

07:00 – 09:00 BREAKFAST (residential guests only) 1st floor, Rootes Building Restaurant

08:00 REGISTRATION OPENS Arts Centre foyer

08:00 – 09:00 **Apheresis Working Group meeting** National Grid Room, 1st floor, Arts Centre

Host: [Dev DATTA](#)

08:30 – 09:30 REFRESHMENTS, NETWORKING + EXHIBITION Mead Gallery, 1st floor, Arts Centre

08:35 – 09:35 **Moderated + Unmoderated Poster Session** Mead Gallery, 1st floor, Arts Centre

Judging panel:

[Chris BYRNE](#) (TBC), [Mike KIRBY](#), [Alan REES](#), [Kurt WIDHALM](#)

Moderated Posters

1

USABILITY OF A WEBTOOL TO ASSIST DECISIONS ON GENOTYPING FOR FAMILIAL HYPERCHOLESTEROLAEMIA – RESULTS FROM A CLINICAL PILOT

[Ashfield-Watt PAL*](#), [Haralambos K](#), [Sharif B](#), [McDowell IFW](#).

FH Wales Research Team, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, CF14 4XN

2

AUDIT OF PCSK9 INHIBITOR PRESCRIBING IN THE NORTH EAST OF ENGLAND

[Banerjee P¹*](#), [Neely RDG¹](#), [Pattman S²](#), [Artham.S³](#), [Carey P³](#)

¹Department of Blood Sciences, Newcastle upon Tyne Hospitals NHS Foundation Trust, UK

²Department of Blood Sciences, Northumbria Healthcare NHS Foundation Trust, UK

³Department of Endocrinology, City Hospitals Sunderland Foundation Trust

3

SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES

[Bellary S¹*](#), [Jodar E²](#), [Seufert J³](#), [Damgaard LH⁴](#), [Gaarsdal Holst A⁴](#), [Leiter L⁵](#)

¹Aston University, Birmingham, UK; ²Universidad Europea de Madrid, Madrid, SPAIN; ³University of Freiburg, Freiburg, Germany; ⁴Novo Nordisk, Soborg, DENMARK; ⁵Li Ka Shing Knowledge Institute and University of Toronto, ON, CANADA

4

HYPERCHOLESTEROLEMIA WITH LOW VERSUS HIGH LIKELIHOOD OF POLYGENIC ORIGIN: A SINGLE CENTRE EXPERIENCE

[A. David^{*1}](#), [J. Cegla¹](#), [S. Walji¹](#), [B. Jones¹](#), [S. Haboosh¹](#), [F. De Lorenzo¹](#), [J. Scott¹](#), [G.R. Thompson¹](#)

¹Lipid Clinic, Hammersmith Hospital, Imperial NHS Trust, London, UK

5

PATIENT EXPERIENCE AT A DEDICATED MULTIDISCIPLINARY NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) CLINIC ENCOMPASSING CARDIOVASCULAR RISK ASSESSMENT AND MANAGEMENT. A NEW MODEL OF CARE?

[Goyale A¹*](#), [Misas MG²](#), [Roccarina D²](#), [Nair DR¹](#) and [Tsochatzis E²](#)

Royal Free London NHS Foundation Trust, London, NW3 2QG

UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London

6

THE IMPACT OF SOCIO-ECONOMIC STATUS ON CASE FINDING FOR FAMILIAL HYPERCHOLESTEROLAEMIA

[L. Gritzmacher¹*](#), [K. Haralambos²](#), [P. Downie¹](#), [G. Bayly¹](#).

¹ Department of Biochemistry, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

² BHF FH Register (PASS) Coordinator, Cardiff University, Cardiff, UK

7

UNUSUAL PRESENTATION OF RHABDOMYOLYSIS AFTER CO-ADMINISTRATION OF STATIN AND CLARITHROMYCIN

*O. Kirresh**, *C. Lunken*

Department of Endocrinology, University College London Hospitals, UK.

8

DUAL PATHOLOGY FOR PANCREATITIS IN PREGNANCY

*O. Kirresh**, *U. Srirangalingam*, *C. Lunken*

Department of Endocrinology, University College London Hospitals, UK.

9

SETTING UP A REGIONAL FH SERVICE; A SUMMARY OF THE ACHIEVEMENTS AND CHALLENGES

*K Mitchell**¹, *J Webster*¹, *C Tuson*², *C Burton*⁴, *P Sutton*³, *R Dunn*³, *D Chandrayay*², *D Narayanan*³, *M Mansfield*⁴, *J Barth*⁴, *A Bandyopadhyay*², *K Haralambos*⁵, *B Power*⁶, *J Jessop*⁶

¹Calderdale and Huddersfield NHS Trust, England; ²York Teaching Hospitals NHS Foundation Trust, England; ³Hull Teaching Hospitals NHS Trust, England; ⁴Leeds Teaching Hospitals NHS Trust, England; ⁵Cardiff and Vale University Hospitals Board, Wales; ⁶Yorkshire and Humber Strategic Clinical Network

10

AN EXPERIENCE OF DEDICATED FH SERVICE IMPLEMENTATION IN HULL AND EAST YORKSHIRE HOSPITALS NHS TRUST

*Paula Sutton*¹, *Rachel Dunn*¹, *Rob Desborough*¹, *Mohammed Malik*², *Aditi Bandyopadhyay*³, *Kate Haramblos*⁴, *Deepa Narayanan*¹.

¹Hull and East Yorkshire Hospitals NHS Trust

²North Lincolnshire and Goole Hospitals NHS Trust

³York Teaching Hospitals NHS Trust

⁴PASS coordinator, Wales.

11

EFFECT OF COMBINATION THERAPY WITH PCSK9 INHIBITORS AND LIPOPROTEIN APHERESIS

*A Pottle**, *C Browne*, *E Neves*, *M Barbir*

Cardiology Department, Harefield Hospital, Royal Brompton & Harefield NHS Foundation Trust, London. UK

12

THE EFFECT OF EXERCISE TRAINING ON LIPID PROFILE: A SYSTEMATIC REVIEW AND META-ANALYSIS

Gina Wood, *Neil A. Smart*

University of New England, Armidale, NSW Australia 2350.

Unmoderated Posters

13

A QUALITY IMPROVEMENT PROJECT: OPTIMISING LIPID LOWERING DIETARY ADVICE VIA GROUP EDUCATION SESSIONS FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE

D. Barrese^{1*}, *A. Lang*¹, *M. Crook*^{2*}, *A. Nassor*^{1*}, *D. Gray*¹, *M. Kagka*^{1*}

¹Department of Nutrition and Dietetics, Guy's and St Thomas' NHS Foundation Trust, London, UK

²Consultant in Clinical Biochemistry and Metabolic Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK

14

A CASE OF RESISTANCE TO PCSK9 INHIBITOR TREATMENT

R. Chaudhry^{1*}, *A. Viljoen*¹

¹Department of Chemical Pathology, Lister Hospital, Stevenage, SG1 4AB, UK

15

METABOLIC SYNDROME CRITERIA AND SUBCLINICAL VASCULAR DISEASE IN ELDERLY MEN

EA Ellins^{1*}, *LT Lennon*², *O Papacosta*², *SG Wannamethee*², *PH Whincup*³, *JP Halcox*¹

¹Institute of Life Sciences, Swansea University Medical School,

²UCL Department of Primary Care & Population Health, UCL Medical School,

³Division of Population Health Sciences and Education, Population Health Research Institute, St George's University of London

16

LCAT DEFICIENCY- A CASE REPORT

Jain A, Hoshi N, Defesche J¹, Nair D R*

Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, NW3 2QG.

¹Molecular Diagnostic Laboratory, Department of Vascular Medicine, Academic Medical centre, Amsterdam, NL-1105 AZ, The Netherlands.

17

PCSK9 INHIBITORS- FITTING THEM INTO ROUTINE PRACTICE IN A LIPID CLINIC

Jain A, Harvey D, Hoshi N, Sharifi M, Dhalla S¹, Nair DR*

Department of Clinical Biochemistry, Royal Free London NHS Foundation Trust, London, NW3 2QG. ¹Pharmacy, Royal Free London NHS Foundation Trust, London, NW3 2QG.

18

EXAMINING THE BURDEN OF ILLNESS IN PATIENTS WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME: RESULTS OF THE IN-FOCUS STUDY, UNITED KINGDOM RESPONDENTS

*Handrean Soran¹, Michael Stevenson², Karren Williams², Brant Hubbard², Richard Jones^{*2}, Basil Issa³*

¹Manchester University Hospital NHS Trust, Manchester, UK; ²Akcea Therapeutics Inc., Cambridge, MA, USA; ³Department of Endocrinology, University Hospital of South Manchester, Wythenshawe, UK

19

SITOSTEROLAEMIA AS A CAUSE OF TENDON XANTHOMATA IN A PATIENT WITH HYPERLIPIDAEMIA

*Ian McDowell^{*1,3} Emily Capener² Heather Wheatley³ Peter Clayton⁴ Andrew Goringe⁵*

1 Cardiff University School of Medicine; 2 Dept of Dietetics, Cardiff and Vale University Health Board; 3 Dept of Medical Biochemistry and Immunology, Cardiff and Vale University Health Board

4 UCL Great Ormond Street Institute of Child Health; 5 Dept of Haematology, Cardiff and Vale University Health Board

20

MEASUREMENT OF ABSORPTION STEROLS IN PATIENTS WITH HYPERCHOLESTEROLAEMIA: IMPROVED DIAGNOSTIC PERFORMANCE WHEN STEROL/CHOLESTEROL RATIOS ARE REPORTED

*A Bowron, E Middling, M Appleton, C Boot, D Neely**

Department of Blood Sciences, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK.

21

LIPID MANAGEMENT WITH PCSK9 INHIBITORS - COMBINATION OR MONOTHERAPY? EXPERIENCE FROM A TERTIARY CARDIAC CENTRE

Neves E, Browne C, Breen J, Davis L, Hayes C, Manning S, Priestley-Barnham L, Barbir M.*

Royal Brompton & Harefield NHS Foundation Trust

22

REVIEW AND ANALYSIS OF A SINGLE CENTRES FIRST ONE HUNDRED PATIENTS PRESCRIBED PCSK9 THERAPY

*K Peers*¹ S Ramachandran^{2,3} A Jones⁴*

1 Advanced Nurse Practitioner in Department of Clinical Chemistry, Heartlands Hospital, Birmingham, England 2 Professor Metabolic Medicine, Department of Clinical Chemistry, Good Hope

Hospital, Birmingham, England 3 Research in Metabolic medicine, Warwick University, Midlands, England 4 Consultant Physician in Clinical Chemistry, Heartlands Hospital, Birmingham, England

23

RECRUITING FAMILIAL HYPERCHOLESTEROLAEMIA (FH) PATIENTS TO THE 100,000 GENOME PROJECT. THE EXPERIENCE OF SPECIALIST NURSES IN THE WESSEX FH SERVICE

Sherman, CI, Cazeaux, A*

Wessex Familial Hypercholesterolaemia Genetics Service, Clinical Genetics, G Level, Princess Anne Hospital, Coxford Road, Southampton. SO16 5YA

SESSION E: Medical & Scientific

Butterworth Hall, Arts Centre

09.45 – 09:50

Opening remarks: *Alan REES*, Medical Director, HEART UK

Chair: *Nigel CAPPS*

09:50 – 10:20

PLENARY SPEAKER 10:

Genomics Update

10:20 – 10:30

Discussion

10:30 - 11:00

REFRESHMENTS, NETWORKING + EXHIBITION

Mead Gallery, 1st floor, Arts Centre

11:00 – 12:15		SESSION F: Medical & Scientific Abstracts of Free Comms <i>Butterworth Hall, Arts Centre</i>		SESSION G: Primary & Health Care Abstracts of Free Comms <i>Cinema, Arts Centre</i>	
		Co-chairs: Julian HALCOX + JAI CEGLA		Co-chairs: Alison POTTLE + Suzanne WATKINS	
11:00 – 11:10	<p>1/ HIGH RATES OF NON-ADHERENCE TO ANTIDIABETIC, ANTIHYPERTENSIVE AND LIPID LOWERING TREATMENT IN PATIENTS WITH TYPE 2 DIABETES REVEALED LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS) URINE ANALYSIS <i>Gupta P^{1,2}, Mohamed AA¹, Patel P¹, Burns A¹, Saeed M¹, Lane D¹, Seidu S^{3,4} and Khunti K^{3,4}</i></p> <p>¹Department of Metabolic Medicine and Chemical Pathology, University Hospitals of Leicester NHS Trust, UK ²Department of Cardiovascular Sciences, University of Leicester, Leicester, UK ³Leicester Diabetes Centre, Leicester General Hospital, Leicester, UK ⁴Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK</p>	11:00 – 11:10	<p>6/ COST-EFFECTIVENESS OF UNIVERSAL SCREENING FOR FAMILIAL HYPERCHOLESTEROLAEMIA (FH) AT AGE 1-2 YEARS <i>A.J. McKay¹, H. Hogan², S.E. Humphries^{3*}, D. Marks⁴, K.K. Ray⁵, A. Miners²</i></p> <p>¹London School of Hygiene and Tropical Medicine (LSHTM), London, UK; ²Department of Health Services Research and Policy, LSHTM, UK; ³Cardiovascular Genetics, UCL, UK; ⁴Department of Public Health, Environments and Society, LSHTM, UK; ⁵Department of Primary Care and Public Health, Imperial College London, UK.</p>		
11:10 – 11:15	Discussion	11:10 – 11:15	Discussion		
11:15 – 11:25	<p>2/ CAN MONOGENIC SEVERE HYPERTRIGLYCERIDEMIA BE DIFFERENTIATED FROM POLYGENIC FORMS THROUGH CLINICAL FEATURES: DATA FROM APPROACH AND COMPASS STUDIES IN FCS AND NON-FCS HYPERTRIGLYCERIDEMIC PATIENTS? <i>Louis O'Dea¹, James MacDougall², Andres Digenio, Brant Hubbard¹, Marcello Arca³, Patrick Moriarty⁴, John Kastelein⁵, Eric Bruckert⁶, Handrean Soran^{*7}</i></p> <p>¹AkceaTherapeutic Inc., Cambridge, MA, USA; ²BioBridges, Wellsley, MA, USA; ³Department of Internal Medicine and Allied Sciences, La Sapienza University of Rome, Rome, Italy; ⁴Department of medicine, Division of Clinical pharmacology, University of Kansas Medical Center, Kansas City, Kansas; ⁵Department of Vascular Medicine, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, Netherlands; ⁶Institut E3M et IHU Cardiometabolique (ICAN), Hôpital Pitié-Salpêtrière, Paris, France; ⁷Manchester University Hospital NHS Trust, Manchester, UK</p>	11:15 – 11:25	<p>7/ FAMILIAL HYPERCHOLESTEROLAEMIA IN THE GENOMIC ERA: IMPROVING THE CLINICAL UTILITY OF CURRENT GENETIC TESTING <i>Knowles C^{1*}, Hills A¹, Watson E¹, Pennock M¹, Dent C¹, Evans J¹, Robinson C¹, Woodward G², Wadsley M², Honeychurch J¹, Williams M¹</i></p> <p>¹ Bristol Genetics Laboratory, Bristol, UK</p>		
11:25 – 11:30	Discussion	11:25 – 11:30	Discussion		
11:30 – 11:40	<p>3/ PROTEIN STRUCTURE ANALYSIS AIDS IN THE INTERPRETATION OF GENETIC VARIANTS OF UNCERTAIN CLINICAL SIGNIFICANCE IDENTIFIED IN THE LDL RECEPTOR <i>A. David¹, S. Ittisoponpisan¹, M.J.E. Sternberg¹</i></p> <p>Centre for Structural Biology, Department of Life Sciences, Imperial College London, London, UK</p>	11:30 – 11:40	<p>8/ FAMILIAL HYPERCHOLESTEROLAEMIA (FH) GENETIC TESTING IN THE UK <i>Haralambos K^{1*}, Humphries SE², Whitmore J³, Datta D⁴, Cather M⁵, Miedzybrodzka Z⁶, Breen J⁷, Gritzmacher L⁸, Hamlen A⁹, Potter A¹⁰, Cazeaux A¹¹, Sherman C¹², Moore A¹², Tyler M¹², Burton C¹³, Webster J¹³, Tuson C¹³, Sutton P¹³, Dunn R¹³, Nicholson K¹⁴, Harvey D¹⁵, Jayne Z¹⁵, Maughan D¹⁶, McDowell IFW¹</i></p> <p>¹Cardiff University, ²Institute Cardiovascular Sciences, London, ³British Heart Foundation, ⁴All Wales FH Cascade Testing Service, ⁵Northern Ireland FH Service, ⁶Scottish FH Service, ⁷Harefield, London FH Service, ⁸Bristol and Bath FH Service, ⁹Gloucestershire FH Service, ¹⁰North East England FH Service, ¹¹Wessex FH Service, ¹²South Yorkshire & North Derbyshire FH Service, ¹³Yorkshire & Humber FH Service, ¹⁴Manchester FH Service, ¹⁵Royal Free FH Service, ¹⁶Doncaster FH Service, UK</p>		
11:40 – 11:45	Discussion	11:40 – 11:45	Discussion		
11:45 – 11:55	<p>4/ CORONARY HEART DISEASE MORTALITY IN SEVERE AND NON-SEVERE FAMILIAL HYPERCHOLESTEROLAEMIA: DATA FROM THE UK SIMON BROOME FH REGISTER <i>S.E. Humphries^{1*}, J.A. Cooper¹, M. Seed², N. Capps³, P.N. Durrington⁴, B.</i></p>	11:45 – 11:55	<p>9/ WHAT DIETETIC SUPPORT IS AVAILABLE TO PATIENTS IN OUTPATIENT LIPID CLINICS IN THE UK? <i>Kinnear, F.J.*¹, Lithander, F.E.¹, Hamilton-Shield, J.P.¹, Main, L.²</i></p> <p>¹NIHR Bristol Biomedical Research Centre (Nutrition theme), Bristol, UK</p>		

		<p><i>Jones⁵, I.F.W. McDowell⁶, H. Soran⁷, H.A.W. Neil⁸ on behalf of the Simon Broome FH Register Group</i></p> <p>¹Cardiovascular Genetics, UCL, London, ²Cardiology, Charing Cross Hospital, U of London; ³Clinical Biochemistry, Princess Royal Hospital, Telford; ⁴Cardiovascular Research Group, U of Manchester; ⁵Investigative Medicine, Imperial College London, ⁶Medical Biochemistry and Immunology, U Hospital of Wales, Cardiff; ⁷Central Manchester University Hospitals, Manchester; ⁸Wolfson College, University of Oxford, UK</p>		² HEART UK- The Cholesterol Charity, Maidenhead, UK
	11:55 – 12:00	Discussion	11:55 – 12:00	Discussion
	12:00 – 12:10	<p>5/ AUTOSOMAL RECESSIVE HYPERCHOLESTEROLAEMIA DUE TO HOMOZYGOUS LDLRAP1 VARIANTS: A BRISTOL CASE REVIEW</p> <p><i>Honeychurch J¹, Hills A¹, Watson E¹, Pennock M¹, Dent C, Evans J, Robinson C, Woodward G¹, Wadsley M¹, Morris A², Cramb, R³, Dawson C³, Soran H⁴, Nicholson K⁴, Williams M¹</i></p> <p>¹Bristol Genetics Laboratory, Bristol, UK ²Alder Hey Children’s Hospital, Liverpool UK ³New Queen Elizabeth Hospital, Birmingham, UK ⁴Old Saint Mary’s Hospital, Manchester, UK</p>	12:00 – 12:10	<p>10/ CARDIOVASCULAR RISK ASSESSMENT IN PATIENTS ATTENDING A PIONEERING SPECIALIST MULTIDISCIPLINARY NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) CLINIC: A CLINICAL EFFECTIVENESS STUDY</p> <p><i>Goyale A¹, Misas MG², Roccarina D², Tsochatzis E² and Nair DR¹</i></p> <p>Royal Free London NHS Foundation Trust, London, NW3 2QG UCL Institute for Liver and Digestive Health, Royal Free Hospital and UCL, London, UK</p>
	12:10 – 12:15	Discussion	12:10 – 12:15	
12:15 - 13:20 (65 mins)	LUNCH, NETWORKING + EXHIBITION			Mead Gallery, 1 st floor, Arts Centre
13:20 – 14:20	SESSION H: Medical & Scientific <i>Butterworth Hall, Arts Centr</i>		SESSION I: Primary & Health Care <i>Cinema, Arts Centre</i>	
	Co-chairs: <i>Handrean SORAN</i> (TBC) + <i>Gordon FERNES</i> (TBC)		Co-chairs: <i>Arun GUPTA</i> + <i>Tracy WALL</i>	
	13:20 – 13:40 (20 mins)	<p>SPEAKER 11:</p> <p>Odessey update</p> <p><i>Professor Tim REYNOLDS</i> (TBC) (sanofi speaker tbc)</p>	13:20 – 13:40 (20 mins)	<p>HC SPEAKER 11:</p> <p>Cutting dietary sugar in primary care: Effect on lipid profiles, liver function, blood pressure, Type 2 Diabetes control and drug budgets</p> <p>Is cutting sugar a magic bullet? Find out how my GP practice gets great results, spends £38,000 less on drugs for diabetes alone and works with patients’ goals.</p> <p><i>Dr David UNWIN</i></p> <p>RCGP National Champion for Collaborative Care and Support Planning in Obesity & Diabetes RCGP clinical expert in diabetes Senior Medical Advisor Diabetes.co.uk Partner Norwood Surgery, Southport, UK</p>
	13:40 – 13:50	Discussion	13:40 – 13:50	Discussion
	13:50 – 14:10 (20 mins)	<p>SPEAKER 12:</p> <p>Fourier data update</p> <p>The Fourier Study was a large trial of PCSK9 inhibitors in cholesterol reduction....what do the subanalyses tell us?</p> <p><i>Dr Derek CONNOLLY</i></p> <p>Consultant Interventional Cardiologist Birmingham City Hospital, Birmingham, UK</p>	13:50 – 14:10 (20 mins)	<p>HC SPEAKER 12:</p> <p>Saturated Fats</p>
	14:10 – 14:20	Discussion	14:10 – 14:20	Discussion
14:20 – 14:30	Comfort break			
14:30 – 14:40	Presentation of prizes and awards <i>Dr Alan REES</i> Medical Director, HEART UK			Butterworth Hall, Arts Centre

14:40 – 15:40

Butterworth Hall, Arts Centre

Question Time debate:

This house believes that Dyslipidaemia rather than Dysglycemia is the predominant risk factor in the promotion of cardiovascular disease in diabetics

Chair – *Dr Alan REES*

For Dyslipidaemia:

Professor Ian YOUNG

Professor Julian HALCOX

For Dysglycemia:

Professor Mike KHAN

Professor John RECKLESS (TBC)

15:40

Conference concludes